Project Grant R01CA300785
Award Date 5/1/26
Completion Date 4/30/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill $384,630 under the Cancer Biology Research program (CFDA 93.396) on April 10, 2026, for a project titled "Identifying Immune-Mediated Mechanisms of RAS Inhibitor Efficacy and Resistance in Pancreatic Cancer." The award, with a completion date of March 31, 2027, funds research designed to elucidate how tumor-immune microenvironment remodeling contributes to the...
- Federal Grant Award Summary The National Cancer Institute awarded Columbia University's Health Sciences Division a $683,970 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2031. This award supports research on tumor-penetrating stromal modification of pancreatic ductal adenocarcinoma (PDAC) through investigation of the αvβ5 integrin pathway. The project focuses on developing and evaluating the IRGD tumor-penetrating peptide as...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
- Federal Project Grant Award Summary Columbia University's Health Sciences Division, in receipt of a $109,080 Project Grant awarded September 1, 2025, by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), is conducting a Phase II investigator-initiated, multicenter randomized controlled trial (RCT) evaluating a novel immunotherapeutic approach for treatment-naive metastatic pancreatic adenocarcinoma (MPDA). The trial compares a four-drug regimen...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $166,000 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) for the period May 1, 2026 through April 30, 2028. This award supports fundamental research investigating mechanisms of resistance to KRAS inhibitors in pancreatic ductal adenocarcinoma (PDAC), which accounts for over 90% of cases driven by KRAS mutations. The project delivers...
- GRANT SUMMARY The National Cancer Institute awarded Weill Medical College of Cornell University a $607,849 Project Grant on August 15, 2025, under the Cancer Treatment Research program (CFDA 93.395) to conduct a five-year research initiative examining mechanisms of genetic and non-genetic resistance to KRAS (Kirsten Rat Sarcoma) inhibition in lung adenocarcinoma and colorectal cancer. The research aims to identify why patients develop resistance to newly emerged mutant-selective and pan-KRAS...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...